Overview

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Status:
Terminated
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
Although Cystic Fibrosis is a complex genetic disease affecting many organs, lung disease is the primary cause of mortality. The objective of this study is to determine the safety and tolerability of SNSP113 in healthy subjects and subjects with stable cystic fibrosis.
Phase:
Phase 1
Details
Lead Sponsor:
Synspira, Inc.